GLP-1 receptor agonist medications (including semaglutide, dulaglutide, liraglutide, exenatide, and lixisenatide) are typically considered for type 2 diabetes when: Triple therapy with other diabetes medications is not effective, not tolerated, or contraindicated The person has a BMI 35 kg/m (adjusted by 2.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) and specific weight-related psychological or medical problems A lower BMI threshold may be appropriate if weight loss would benefit other obesity-related comorbidities Insulin would not be appropriate or acceptable to the person Treatment is usually continued only if there is a beneficial metabolic response (reduction in HbA1c and weight) after 6 months
Thyroid dysfunction, insulin resistance, polycystic ovary syndrome, certain medications (like corticosteroids or some antidepressants), and hormonal imbalances can all impair weight loss response to semaglutide
Early adjustments can make the difference between a smooth transition and a discouraging experience that leads to discontinuation
Semaglutide (20 mg) is a synthetic peptide commonly studied in metabolic and endocrine research
Sirlin American Journal of Roentgenology .2026;[Epub] CrossRef Characterization of Post-translational Modification in Metabolic Dysfunction-Associated Steatohepatitis: Acetylation, Lactylation, and Phosphorylation Kuan Li, Yundong Li, Yuqing Zhang, Shuxian Song, Chengzhou Pa, Chen Du, Lianjun Yang, Guoyou Xue, Hongqiang Gao Journal of Lipid Research .2026